Exhibit 99.1
Vigil Neuroscience Reports Third Quarter 2023 Financial Results
and Provides Business Update
Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter
First participant dosed in Phase 1 study of VG-3927, the first and only small molecule TREM2
agonist in clinical development for potential treatment of Alzheimers disease
Announced VGL101 complete Phase 1 data
analysis and Phase 2 IGNITE trial design at 2023 ANA Annual Meeting
WATERTOWN, Mass., November 7, 2023 (GLOBE NEWSWIRE)
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the third quarter
ended September 30, 2023, and provided an update on recent progress.
We continue to make significant progress in advancing our novel TREM2
agonist candidatesVGL101 in ALSP and VG-3927 in Alzheimers disease, and believe we are well-positioned to become a leader in neurodegenerative drug development, said Ivana
Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. Importantly, we are diligently advancing our Phase 2 IGNITE trial, the first interventional study in ALSP, and expect to report our interim results
from the first six patients treated for six months with VGL101 this quarter. In September, we also proudly introduced our oral small molecule TREM2 agonist candidate, VG-3927, with the opening of our IND. We
dosed our first participant in our Phase 1 clinical trial in healthy volunteers last month and expect to share interim results in mid-2024.
As the only company known to have two TREM2 modalities, we have achieved critical milestones to support our mission to bring transformative therapies to
patients with both rare and common neurodegenerative diseases, added Dr. Magovčević-Liebisch. With our unique precision medicine approach and dedicated team of industry leaders, we look forward to the continued development
of our clinical programs to serve patient populations with high unmet need.
1